Home/Filings/4/0001209191-21-063263
4//SEC Filing

Suria Hamza 4

Accession 0001209191-21-063263

CIK 0001370053other

Filed

Nov 4, 8:00 PM ET

Accepted

Nov 5, 6:24 PM ET

Size

14.5 KB

Accession

0001209191-21-063263

Insider Transaction Report

Form 4
Period: 2021-11-04
Suria Hamza
DirectorPresident, CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2021-11-04$1.12/sh+6,059$6,78673,695 total
  • Sale

    Common Stock

    2021-11-04$35.00/sh6,059$212,06567,636 total
  • Sale

    Common Stock

    2021-11-05$35.00/sh14,302$500,57067,636 total
  • Exercise/Conversion

    Common Stock

    2021-11-05$1.12/sh+14,302$16,01881,938 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-11-046,05914,302 total
    Exercise: $1.12Exp: 2021-12-08Common Stock (6,059 underlying)
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-11-0514,3020 total
    Exercise: $1.12Exp: 2021-12-08Common Stock (14,302 underlying)
Footnotes (3)
  • [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
  • [F2]The stock option grant was issued on December 9, 2011, is fully vested and exercisable until its expiration date of December 8, 2021.
  • [F3]In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,155,538 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly.

Issuer

ANAPTYSBIO, INC

CIK 0001370053

Entity typeother

Related Parties

1
  • filerCIK 0001654495

Filing Metadata

Form type
4
Filed
Nov 4, 8:00 PM ET
Accepted
Nov 5, 6:24 PM ET
Size
14.5 KB